2025
Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study
Bernstein J, Betschel S, Busse P, Banerji A, Wedner H, Manning M, Zaragoza-Urdaz R, Anderson J, Gagnon R, Baptist A, Soteres D, Lumry W, Craig T, Petroni D, Hsu F, Nova Estepan D, Juethner S, Watt M, Khutoryansky N, Zuraw B. Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study. Advances In Therapy 2025, 1-20. DOI: 10.1007/s12325-025-03226-3.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsLong-term prophylaxisHereditary angioedemaHAE attack ratesPost-baseline safety assessmentProphylaxis of hereditary angioedemaConclusionReal-world dataInjection site reactionsAttack rateReal-world studyYears of ageFemale patientsLanadelumabSite reactionsAdverse eventsFollow-upSafety signalsSafety dataEMPOWER studyPatientsDeficiency typeAngioedemaLow attack rateSustained effectPost-baseline
2024
Overestimation of Severe Acute Respiratory Syndrome Coronavirus 2 Household Transmission in Settings of High Community Transmission: Insights From an Informal Settlement Community in Salvador, Brazil
Ticona J, Nery N, Hitchings M, Belitardo E, Fofana M, Dorión M, Victoriano R, Cruz J, Santana J, de Moraes L, Cardoso C, Ribeiro G, Reis M, Khouri R, Costa F, Ko A, Cummings D. Overestimation of Severe Acute Respiratory Syndrome Coronavirus 2 Household Transmission in Settings of High Community Transmission: Insights From an Informal Settlement Community in Salvador, Brazil. Open Forum Infectious Diseases 2024, 11: ofae065. PMID: 38516384, PMCID: PMC10957159, DOI: 10.1093/ofid/ofae065.Peer-Reviewed Original ResearchSARS-CoV-2Household transmissionRT-PCR positive casesSecondary attack rateAttack rateSARS-CoV-2 infectionSARS-CoV-2 Omicron variantRisk of infectionCommunity acquisitionTherapeutic optionsCOVID-19-related symptomsCase-finding studyHousehold contactsAcquisition of SARS-CoV-2Increased riskSymptom onsetSecondary infectionBooster vaccinationSevere outcomesBiweekly visitsHighest attack rateRT-PCRInfectionCOVID-19 severe outcomesOmicron BA
2022
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak at a College With High Coronavirus Disease 2019 (COVID-19) Vaccination Coverage—Connecticut, August 2021–September 2021
Bart S, Curtiss CC, Earnest R, Lobe-Costonis R, Peterson H, McWilliams C, Billig K, Hadler JL, Grubaugh ND, Arcelus VJ, Sosa LE. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak at a College With High Coronavirus Disease 2019 (COVID-19) Vaccination Coverage—Connecticut, August 2021–September 2021. Clinical Infectious Diseases 2022, 75: s243-s250. PMID: 35675696, PMCID: PMC9214140, DOI: 10.1093/cid/ciac422.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionLaboratory-confirmed SARS-CoV-2 infectionSARS-CoV-2 casesHigh vaccination coverageMultivariate logistic regressionDelta variant outbreakSARS-CoV-2 outbreakVaccine seriesVaccination historyVaccination coverageUnvaccinated studentsViral testsVariant outbreakInfected studentsUninfected studentsInfectionWeekly testingLogistic regressionAttack rateConnecticut DepartmentPublic healthViral sourcesViral genome sequencesOutbreakSocial gatheringsThe Impact of Testing Capacity and Compliance With Isolation on COVID-19: A Mathematical Modeling Study
Yu Z, Keskinocak P, Steimle L, Yildirim I. The Impact of Testing Capacity and Compliance With Isolation on COVID-19: A Mathematical Modeling Study. AJPM Focus 2022, 1: 100006. PMID: 36942015, PMCID: PMC9119710, DOI: 10.1016/j.focus.2022.100006.Peer-Reviewed Original ResearchTesting capacityCOVID-19Infection attack rateInfectious respiratory diseaseFuture pandemicsAdditional testing capacityEarly startLow testing capacityRespiratory diseaseBenefits of testingDiagnostic testingAbsence of testingDiagnostic testsAttack rateDays of delayHigh compliancePublic healthInfection spreadDiseaseStart of testingSignificant benefitsPandemicComplianceMathematical modeling studiesPotential benefitsThe balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants
Kim D, Keskinocak P, Pekgün P, Yildirim İ. The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants. Scientific Reports 2022, 12: 7493. PMID: 35523832, PMCID: PMC9075929, DOI: 10.1038/s41598-022-11060-8.Peer-Reviewed Original ResearchConceptsOverall public health impactInfection attack rateCOVID-19 vaccineSARS-CoV-2Public health impactVaccine effectivenessAdverse outcomesMultiple vaccinesInitial efficacySuccessful immunization strategyImmunization strategiesVaccineLow-income countriesAttack rateEfficacyCOVID-19COVID-19 pandemicHealth impactsInfection spreadRecovered-deceased [SI(Q/F)RD] modelEfficacy levelsPandemicHospitalizationVaccinationVariantsSARS-CoV-2 Attack Rate and Population Immunity in Southern New England, March 2020 to May 2021
Tran TN, Wikle NB, Yang F, Inam H, Leighow S, Gentilesco B, Chan P, Albert E, Strong ER, Pritchard JR, Hanage WP, Hanks EM, Crawford FW, Boni MF. SARS-CoV-2 Attack Rate and Population Immunity in Southern New England, March 2020 to May 2021. JAMA Network Open 2022, 5: e2214171. PMID: 35616938, PMCID: PMC9136627, DOI: 10.1001/jamanetworkopen.2022.14171.Peer-Reviewed Original ResearchConceptsHigh vaccine coveragePopulation immunityPublic health agenciesVaccine coverageVaccination campaignMAIN OUTCOMECOVID-19 positive test resultsSARS-CoV-2 attack ratesIntensive care unit occupancyHealth agenciesLarge epidemic waveProportion of vaccinesAttack rateObservational case seriesPopulation-level immunitySARS-CoV-2Median ageCase seriesCOVID-19 casesPercentage of individualsVaccination planningDelta variantOngoing epidemicPandemic settingVaccineA review of COVID-19 transmission dynamics and clinical outcomes on cruise ships worldwide, January to October 2020
Willebrand KS, Pischel L, Malik AA, Jenness SM, Omer SB. A review of COVID-19 transmission dynamics and clinical outcomes on cruise ships worldwide, January to October 2020. Eurosurveillance 2022, 27: 2002113. PMID: 34991781, PMCID: PMC8739343, DOI: 10.2807/1560-7917.es.2022.27.1.2002113.Peer-Reviewed Original ResearchConceptsCOVID-19 casesCOVID-19COVID-19-associated deathsAttack rateMedian attack rateCOVID-19 outbreakUnited States CentersSARS-CoV-2Mean attack rateClinical outcomesMedian numberCOVID-19 transmission dynamicsEpidemiological informationDisease controlDiamond PrincessSuperspreader eventsStates CentersSusceptible populationTransmission dynamicsPrevention's listOutbreakInternational spread
2021
386. A Systematic Review of COVID-19 Transmission Dynamics and Clinical Response on Cruise Ships Globally Between January and October 2020
Willebrand K, Pischel L, Malik A, Jenness S, Omer S. 386. A Systematic Review of COVID-19 Transmission Dynamics and Clinical Response on Cruise Ships Globally Between January and October 2020. Open Forum Infectious Diseases 2021, 8: 294-295. PMCID: PMC8644941, DOI: 10.1093/ofid/ofab466.587.Peer-Reviewed Original ResearchCOVID-19 casesCOVID-19Systematic reviewAttack rateMedian attack rateSARS-CoV-2Full-text articlesMean attack rateClinical responseMedian numberCOVID-19 transmission dynamicsEpidemiologic informationNumber of casesPRIMSA guidelinesDisease controlFinal analysisDiamond PrincessText articlesCOVID-19 outbreakSusceptible populationTransmission dynamicsMEDLINEOutbreakInternational spreadPercentResource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach
Kim D, Pekgün P, Yildirim İ, Keskinocak P. Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach. Vaccine 2021, 39: 6876-6882. PMID: 34688498, PMCID: PMC8520874, DOI: 10.1016/j.vaccine.2021.10.025.Peer-Reviewed Original ResearchConceptsInfection attack rateVaccine typesDifferent vaccine typesResource-limited countriesHigh-efficacy vaccinesDifferent study parametersVaccine shortageEfficacy vaccineHealth outcomesLife-saving vaccinesVaccineVaccine distributionLow efficacyAttack rateStudy parametersEfficacyHigh efficacyCOVID-19COVID-19 pandemicDeceased (SIRD) modelDifferent resource allocation decisionsLimited accessSignificance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation
Fujimoto AB, Keskinocak P, Yildirim I. Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation. Vaccine 2021, 39: 5055-5063. PMID: 34274126, PMCID: PMC8233959, DOI: 10.1016/j.vaccine.2021.06.067.Peer-Reviewed Original ResearchConceptsInfection attack rateAntibody testingSARS-CoV-2-specific antibodiesSpecific antibody testingAttack rateCOVID-19 vaccineSingle-dose vaccineCOVID-19 vaccine allocationDose vaccineSerology testingLimited vaccinesEligible individualsVaccine deploymentVaccination planVaccine supplySusceptible individualsNumber of casesRecovered (SIR) compartmental modelPeak dayUse of antibodiesVaccine allocationVaccinePeak infectionVaccinationSpecific antibodiesHow to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19
Accorsi E, Qiu X, Rumpler E, Kennedy-Shaffer L, Kahn R, Joshi K, Goldstein E, Stensrud M, Niehus R, Cevik M, Lipsitch M. How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19. European Journal Of Epidemiology 2021, 36: 179-196. PMID: 33634345, PMCID: PMC7906244, DOI: 10.1007/s10654-021-00727-7.Peer-Reviewed Original ResearchConceptsRisk Factors StudyPublic health scientistsPotential sources of biasBody of literatureSources of biasStudy designFactor studiesHealth scientistsCategories of studiesObservational studyCOVID-19Selection biasPotential biasSecondary attack rateRisk of infectionGeographical areasAttack rateRiskSusceptibility to infectionStudy of COVID-19Cross-sectional seroprevalenceConfoundingCoronavirus diseaseInterventionCohabitation COVID-19 transmission rates in a United States suburban community: A retrospective study of familial infections
D'Onofrio L, Buono F, Cooper M. Cohabitation COVID-19 transmission rates in a United States suburban community: A retrospective study of familial infections. Public Health 2021, 192: 30-32. PMID: 33611168, PMCID: PMC7816609, DOI: 10.1016/j.puhe.2021.01.003.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Household contactsIndex caseInfection rateSARS-CoV-2 test resultsFamilial infectionInfection attack rateCoronavirus disease 2019Electronic Disease Surveillance SystemDisease surveillance systemsRetrospective reviewRetrospective studyMedical recordsRisk factorsSecondary casesDisease 2019Serious symptomsViral transmissionContagious virusAttack rateGlobal infection rateHome addressCOVID-19AgeInfection
2019
Cryptosporidiosis among solid organ transplant recipient attendees at a summer camp
McAteer J, Jernigan S, Mao C, Gonzalez MD, Watson RJ, Liverman R, Angelo M, M. H, Shane A, Yildirim I. Cryptosporidiosis among solid organ transplant recipient attendees at a summer camp. Pediatric Transplantation 2019, 24: e13649. PMID: 31885132, DOI: 10.1111/petr.13649.Peer-Reviewed Original ResearchConceptsTransplant recipientsSolid organ transplant recipientsKidney transplant recipientsRetrospective cohort studyOrgan transplant recipientsPediatric transplant recipientsOverall attack rateAcute rejection eventsLong-term interventionsImmunosuppressive therapySymptom durationCohort studyRisk factorsNotable burdenStool specimensCryptosporidiosis infectionEtiologic agentRejection eventsAttack rateFurther outbreaksInfectionRecipientsCryptosporidium hominisCryptosporidiosisOutbreakImpact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region
Rodriguez-Barraquer I, Costa F, Nascimento EJM, Nery N, Castanha PMS, Sacramento GA, Cruz J, Carvalho M, De Olivera D, Hagan JE, Adhikarla H, Wunder EA, Coêlho DF, Azar SR, Rossi SL, Vasilakis N, Weaver SC, Ribeiro GS, Balmaseda A, Harris E, Nogueira ML, Reis MG, Marques ETA, Cummings DAT, Ko AI. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science 2019, 363: 607-610. PMID: 30733412, PMCID: PMC8221194, DOI: 10.1126/science.aav6618.Peer-Reviewed Original ResearchConceptsZika virusZIKV NS1 antigenAttack rateZika virus emergenceHigh antibody titersDengue-endemic regionsZIKV immunityClinical outcomesDengue immunityZIKV infectionAntibody titersNS1 antigenRisk factorsEndemic regionsDengue virusImmunityVirusRiskVirus emergenceFuture transmissionCohortSymptomsInfectionAntigenTiters
2012
<i>Neisseria meningitis</i> serogroup X outbreak in Burkina Faso, 2009-2010
Yaro S, Drabo A, Ouangraoua S, Kirakoya-Samadoulougou F, Mueller J, Sanou O, Tall H, Jaillard P, Njanpop-Lafourcade B, Macq J, Robert A, Ouedraogo J. Neisseria meningitis serogroup X outbreak in Burkina Faso, 2009-2010. Open Journal Of Internal Medicine 2012, 2012: 41-49. DOI: 10.4236/ojim.2012.22010.Peer-Reviewed Original ResearchVaccine introductionPolymerase chain reactionSerogroup XPneumococcal vaccine introductionContacts of patientsReference laboratoryCountries' national guidelinesPilot districtsAdequate antibioticsCentre MurazCampaign vaccinationSecondary casesPolyvalent vaccineSerogroup distributionFluid collectionNational guidelinesVaccine compositionCSF samplesEpidemiological seasonFaster careLaboratory capacityAttack rateChain reactionBobo-DioulassoPatients
2009
Assessing yellow fever risk in the Ecuadorian Amazon
Izurieta RO, Macaluso M, Watts DM, Tesh RB, Guerra B, Cruz LM, Galwankar S, Vermund SH. Assessing yellow fever risk in the Ecuadorian Amazon. Journal Of Global Infectious Diseases 2009, 1: 7-13. PMID: 20300380, PMCID: PMC2840941, DOI: 10.4103/0974-777x.49188.Peer-Reviewed Original ResearchYellow fever casesYellow fever infectionFever infectionFever casesSerum glutamic oxaloacetic transaminaseSerum glutamic pyruvicHumoral immune responseCross-sectional studyDengue-2 infectionsIgG-specific antibodiesGlutamic oxaloacetic transaminaseYellow fever outbreaksYellow fever riskMilitary personnelSeroepidemiological methodsClinical symptomsRisk factorsImmune responseOxaloacetic transaminaseGlutamic pyruvicFever riskFever outbreakAttack rateSpecific antibodiesYellow fever
2000
Epidemic nephritis in Nova Serrana, Brazil
Baiter S, Benin A, Pinto S, Teixeira L, Alvim G, Luna E, Jackson D, LaClaire L, Elliott J, Facklam R, Schuchat A. Epidemic nephritis in Nova Serrana, Brazil. The Lancet 2000, 355: 1776-1780. PMID: 10832828, DOI: 10.1016/s0140-6736(00)02265-0.Peer-Reviewed Original ResearchConceptsThroat culturesControl householdsCase-control studyNova SerranaS. zooepidemicusUnpasteurized dairy productsRecent patientsAcute nephritisEpidemic nephritisNephritisPatientsCase householdsLarge outbreakFurther casesOutbreak strainDairy productsAttack rateOutbreaks of nephritisDairy foodsStreptococcus equiCluster designBovine mastitisFamily membersZooepidemicusOutbreak
1986
The Role of Parvovirus B19 in Aplastic Crisis and Erythema Infectiosum (Fifth Disease)
Chorba T, Coccia P, Holman R, Tattersall P, Anderson L, Sudman J, Young N, Kurczynski E, Saarinen U, Moir R, Lawrence D, Jason J, Evatt B. The Role of Parvovirus B19 in Aplastic Crisis and Erythema Infectiosum (Fifth Disease). The Journal Of Infectious Diseases 1986, 154: 383-393. PMID: 3016109, DOI: 10.1093/infdis/154.3.383.Peer-Reviewed Original ResearchConceptsErythema infectiosumAplastic crisisParvovirus B19B19-specific IgMSecondary attack rateSimultaneous outbreaksThroat garglesB19 infectionClinical entityRecent infectionAsymptomatic infectionSusceptible contactsPatientsInfectionB19Attack rateSerumComparison groupIgMHousehold membersOutbreakGargleEpidemiologyUrine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply